交易 uniQure N.V. - QURE 差價合約

交易條件

• 類型該金融市場可進行差價合約交易。了解更多：差價合約: 差價合約
• 點差: 0.09
• 長倉隔夜倉息調整長倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用-0.022262 %(-$0.45)使用杠杆的交易規模（大約值）$2,000.00來自杠杆的資金 - 美元（大約值）$1,000.00前往平台: -0.02226%
• 短倉隔夜倉息調整短倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用0.00004 %($0.00)使用杠杆的交易規模（大約值）$2,000.00來自杠杆的資金 - 美元（大約值）$1,000.00前往平台: 0.00004%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 50.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價保證止損 (GSL) 費用僅在 GSL 被觸發時收取。更多詳情請參閱我們網站的「服務費用」 頁面。: 1%

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: -0.022262 %
  (-$0.45)

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: 0.00004 %
  ($0.00)

主要統計數據

• 前收盤價: 23.31
• 開倉: 23.21
• 1 年變化: -1.15%
• 日區間: 22.78 - 23.53

交易 uniQure N.V. - QURE

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington''s disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer''s disease; and AMT-210 that is in preclinical trial to treat Parkinson''s disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.